☰ Show/Hide Menu

Publications

You are here

  1. Home
  2. Publications
Title
Info

2018

  1. Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models.
    Kuipers, A., Moll, G.N., Wagner, E., Franklin, R. Peptides

2017

  1. Phage display and selection of lanthipeptides on the carboxy-terminus of the gene-3 minor coat protein.
    Urban J.U., Moosmeier, M.A., Aumüller, T., Thein, M., Bosma, T., Rink, R., Groth, K., Zulley, M., Siegers, K., Tissot, K., Moll, G.N., Prassler, J.Nature Comm. 2017 Nov 15;8(1):1500
  2. Semi-microbiological synthesis of an active lysinoalanine-bridged analog of glucagon-like-peptide-1.
    Kuipers, A., de Vries, L., de Vries, M.P., Rink, R., Bosma, T., Moll, G.N. Peptides 91, 33-39.
  3. Mutagenesis of nisin's leader peptide proline strongly modulates export of precursor nisin.
    Plat, A., Kuipers, A., Crabb, J., Rink, R., Moll, G.N. Antonie Van Leeuwenhoek 110, 321-330.
  4. Mechanistic aspects of lanthipeptide leaders.
    Plat, A., Kuipers, A., Rink, R., Moll, G.N. Curr. Protein Pept. Sci. 14, 85-96.

2015

  1. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
    Carlucci, G., Kuipers, A., Ananias, H.J., de Paula Faria, D., Dierckx, R.A., Helfrich, W., Rink, R., Moll, G.N., de Jong IJ, Elsinga PH. Peptides 67, 45-54.

2012

  1. Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury.
    Wagenaar, G.T., Laghmani, E.H., Fidder, M., Sengers, R.M., de Visser, Y.P., de Vries, L., Rink, R., Roks, A,J., Folkerts, G., Walther, F.J.
  2. The effect of the thioether-bridged, stabilized Angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction.
    Durik, M., van Veghel, R., Kuipers, A., Rink, R, Haas, Jimoh Akanbi, M., Moll, G., Danser, A.H., Roks, A.J. Int J Hypertens 2012, 536426.

2011

  1. Bacterial display and screening of posttranslationally thioether-stabilized peptides.
    Bosma, T., Kuipers, A., Bulten, E., de Vries, L., Rink, R., Moll, G.N. Appl. Environ. Microbiol. 77, 6794-801.

2010

  1. To protect peptide pharmaceuticals against peptidases.
    Rink, R., Arkema-Meter, A., Baudoin, I., Post, E., Kuipers, A., Nelemans, S.A., Haas-Jimoh-Akanbi, M., Moll, G.N. Pharmacol. Toxicol. Methods. 61, 210–218

2009

  1. A biological stabilization technology for peptide drugs: enzymatic introduction of thioether-bridges.
    Moll, G.N. Kuipers, A., de Vries, L., Bosma, T., Rink, R. Drug Discov Today: Technol. doi:10.1016/j.ddtec.2009.03.
  2. Translocation of a thioether-bridged azurin peptide fragment via the sec pathway in Lactococcus lactis
    Kuipers, A., Rink, R., Moll, G.N. Appl. Environ. Microbiol. 75, 3800-3802
  3. Mechanistic dissection of the enzyme complexes involved in the biosynthesis of nisin and lacticin 3147.
    Kuipers, A., Meijer-Wierenga, J., Rink, R., Kluskens, L.D., and Moll, G.N. (2008), Appl. Environ. Microbiol. 74, 6591-6597
  4. Angiotensin-(1-7) with thioether-bridge: an ACE-resistant, potent Ang-(1-7) analogue
    Kluskens, L.D., Nelemans, S.A., Rink, R., de Vries, L., Meter-Arkema, A., Wang, Y., Walther, T., Kuipers, A., Moll, G. N., and Haas, M. J. Pharmacol. Exper. Ther. 328, 849-854